Neurology
Within the last few years the CRF has forged very strong links with neurologists both in St James’s hospital and Beaumont hospital. The CRF works on epilepsy studies with Dr Doherty.
We have also conducted Phase I overnight studies with Prof Orla Hardiman, researching treatment in motor neuron disease.
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| Fusion | A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients with Fused in Sarcoma Mutations (FUS-ALS) | Clinical trial (NCT04768972) | Ionis Pharmaceuticals | Commercial: Industry |
| Anqur | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF QRL-201 IN AMYOTROPHIC LATERAL SCLEROSIS | Clinical trial (NCT05633459) | QurAlis Corporation | Commercial: Industry |
| Clou | A randomized, double-blind, double- dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by xtended treatment with open-label remibrutinib | Clinical trial (NCT05147220) | Novartis | Commercial: Industry |
| AVP-786 | A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type | Clinical trial (NCT03393520) | Avanir Pharmaceuticals | Commercial: Industry |
| EMG studies initiative | EMG studies initiative (tests will be carried out according to usual clinical practice) | Observational-non invasive | TCD and MND Charity | Non-commercial: Academic |
| RECONNECT (Zynerba) | A Randomized, Double-Blind, Placebo-Controlled, Multiple-Centre Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome - RECONNECT | Clinical Trial (NCT03614663) | Zynerba | Commercial: Industry |
| CDKL5 Deficiency Disorder (CDD) | Analysis of alpha-tubulin post-translational modifications using infra-red western blot in plasma sampled from CDKL5 Deficiency Disorder (CDD) patients | Observational-non invasive | Non-commercial: Hospital | University |
| TMS | Characterising Network Disruption in Human Neurodegeneration: A Spectral EEG and TMS based approach in Amyotrophic Lateral Sclerosis | Clinical Trial (NCT04918251) | Science Foundation Ireland | Non-commercial: Academic |
| PREVENT | The PREVENT Research Programme - Pilot and Feasibility Stage | Observational with invasive tests | University of Edinburgh | Non-commercial: Academic |
| CONCUSSION | Assessment of Concussion in contact sport | Observational with radiology or blood tests | N/A | Non-commercial: Hospital |
| MotorMarker | impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis | Observational with radiology or blood tests | N/A | Non-commercial: Academic |
| EEG-MMN and EEG-SART | Characterising Network Disruption in Human Neurodegeneration: A Spectral EEG and TMS based approach in Amyotrophic Lateral Sclerosis | Observational-non invasive | N/A | Non-commercial: Academic |
| GMI AZD | The Genomic Basis of Alzheimer's disease in Ireland | Observational with radiology or blood tests | GMI | Commercial: Industry |
| EVOKE | A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE) | Clinical Trial (NCT04777396) | Novo Nordisk | Commercial: Industry |
| EVOKE Plus | A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus) | Clinical Trial (NCT04777409) | Novo Nordisk | Commercial: Industry |
| DYNE | A randomized, Double- blind, Placebo- controlled, Multiple ascending dose study assessing safety, tolerability, pharmacodynamics, efficacy and pharmacokinetics of DYNE-251 Administered to participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping | Clinical Trial | Dyne Therapeutics | Commercial : Industry |
| RECONNECT OLE | An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children, Adolescents, and Young Adults with Fragile X Syndrome | Clinical Trial | Zynerba Pharmaceuticals | Commercial: Industry |
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| Wave | A Multicenter, Randomized, Double-blind, Placebocontrolled,Phase 1b/2a Study of WVE-004Administered Intrathecally to Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) orFrontotemporal Dementia (FTD) | Clinical trial (NCT04931862) | Wave Life Sciences | Commercial: Industry |
| SynaG | Identifying Biomarkers for Autism Spectrum Disorder and Neurodevelopmental Disorders in Individual Carriers of Rare Genetic Risk Variants | Observational with radiology or blood tests | EU Innovative Medicines Scheme | Charity |
| BIOVASC | The BIOVASC Study (Biomarkers and Imaging Of Vulnerable Atherosclerosis in Symptomatic Carotid artery disease) | Observational with invasive tests | Neurovascular Research Centre, UCD | Non-commercial: Academic |
| MolGen | Whole Genome Sequencing of Multiplex Families afected by Autism Spectrum Disorder and Major Neuropsychiatric Conditions | Observational with radiology or blood tests | Wellcome Trust | Charity |
| BIIB078 | A Phase I Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults with C9ORF72-Associated Amyotrophic Lateral Sclerosis | Clinical Trial (NCT03626012) | Biogen | Commercial: Industry |
| UCB Study | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of Padsevonil As Adjunctive Treatment Of Focal-Onset Seizures In Adult Subjects With Drug-Resistant Epilepsy | Clinical trial (NCT03739840) | UCB | Industry |
| Renew | Renew Research, LLC - RenewTM NCP-5 - 1001, A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment due to Alzheimer's Disease or Mild Dementia of the Alzhemier's Type (Pro00027434) | Medical device study (NCT03721705) | Renew | Commercial: Industry |
| EEG in ALS Patients | High resolution Spectral EEG recording in Amyotrophic lateral sclerosis; correlation with comprehensive neuropsychological profiling | Observational with invasive tests | N/A | Academic |
| EEG and epilepsy | The Acute neroimaging, neurophysiology and clinical data correlation in patients presenting to the emergency Department within 24 hours of seizure onset and at 6 weeks post ictally | Observational with invasive tests | N/A | Academic |
| IHF Stroke Biomarker (DCCR) | IHF Stroke Biomarker | Observational with radiology or blood tests | National (Government agency) | |
| IMAGEN | IMAGEN Study | Observational with radiology or blood tests | Non-commercial: Academic | |
| BIOMARKAPD | BIOMARKAPD- A pilot study on the utility of CSF and blood biomarkers in the delineation of the aetiopathology of cognitive impairment and in the prediction of conversion of mild cognitive impairment to dementia. | Observational with radiology or blood tests | National (Government agency) | |
| NILVAD | NILVAD - A European Multicentre Double Blind Placebo Controlled trial of Nilvadipine in Mild to Moderate Alzhelmer's disease | Clinical trial (NCT02017340) | European Commission: FP7 Grant | Non-commercial: Academic |
| MCI | Evoked Potentials (Eps) used in clinical practice | Observational with invasive tests | Health Research Board | National (Government agency) |
| Evoked EPs | Evoked Potentials (Eps) used in clinical practice | Observational with radiology or blood tests | Medical Directorate | Non-commercial: Hospital |